UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

---------
FORM 10-Q
---------

(Mark One)

X Quarterly report pursuant to Section 13 or 15(d) of the Securities
----- Exchange Act of 1934

For the period ended June 30, 2001

Transition report pursuant Section 13 or 15(d) of the Securities
----- Exchange Act of 1934

Commission File Number: 0-27078

HENRY SCHEIN, INC.
(Exact name of registrant as specified in its charter)

DELAWARE 11-3136595
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)

135 Duryea Road
Melville, New York
(Address of principal executive offices)

11747
(Zip Code)

Registrant's telephone number, including area code: (631) 843-5500

Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days:

Yes X No
----- -----

As of August 10, 2001 there were 42,526,485 shares of the Registrant's Common
Stock outstanding.

HENRY SCHEIN, INC. AND SUBSIDIARIES
INDEX

Page
----
PART I. FINANCIAL INFORMATION

ITEM 1. Consolidated Financial Statements:
Balance Sheets as of June 30, 2001 and December 30, 2000 .................. 3

Statements of Operations for the three and six months ended
June 30, 2001 and June 24, 2000 ...................................... 4

Statements of Cash Flows for the six months ended
June 30, 2001 and June 24, 2000 ...................................... 5

Notes to Consolidated Financial Statements ................................ 6

ITEM 2. Management's Discussion and Analysis of
Financial Condition and Results of Operations ........................ 12

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk ................ 18

PART II. OTHER INFORMATION

ITEM 1. Legal Proceedings ......................................................... 19

ITEM 4. Submission of Matters to a Vote of Security Holders ....................... 20

ITEM 6. Exhibits and Reports on Form 8-K .......................................... 20

Signature ................................................................. 21

PART 1. FINANCIAL INFORMATION
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

HENRY SCHEIN, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)

June 30, 2001 December 30, 2000
-------------------- --------------------
(unaudited) (audited)

ASSETS
Current assets:
Cash and cash equivalents ................................................. $ 75,847 $ 58,362
Accounts receivable, less reserves of $28,506 and $27,556, respectively ... 366,316 371,668
Inventories ............................................................... 258,662 276,473
Deferred income taxes ..................................................... 21,842 21,001
Prepaid expenses and other ................................................ 46,169 60,900
-------------------- --------------------
Total current assets ............................................ 768,836 788,404
Property and equipment, net of accumulated depreciation and amortization
of $83,061 and $73,134, respectively ...................................... 96,650 94,663
Goodwill and other intangibles, net of accumulated amortization
of $49,739 and $44,419, respectively ...................................... 278,768 292,018
Investments and other .......................................................... 57,533 55,983
-------------------- --------------------
$ 1,201,787 $ 1,231,068
==================== ====================

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable .......................................................... $ 169,629 $ 216,535
Bank credit lines ......................................................... 9,117 4,390
Accruals:
Salaries and related expenses ........................................ 38,671 39,830
Merger and integration, and restructuring costs ...................... 8,506 13,735
Other ................................................................ 80,453 84,288
Current maturities of long-term debt ...................................... 4,596 6,079
-------------------- --------------------
Total current liabilities ....................................... 310,972 364,857
Long-term debt ................................................................. 250,799 266,224
Other liabilities .............................................................. 13,449 12,931
-------------------- --------------------
Total liabilities ............................................... 575,220 644,012
-------------------- --------------------
Minority interest .............................................................. 6,954 7,996
-------------------- --------------------
Stockholders' equity:
Common stock, $.01 par value, authorized 120,000,000,
issued: 42,521,192 and 41,946,284, respectively ...................... 425 419
Additional paid-in capital ................................................ 386,276 373,413
Retained earnings ......................................................... 260,071 225,029
Treasury stock, at cost, 62,479 shares .................................... (1,156) (1,156)
Accumulated comprehensive loss ............................................ (25,599) (18,179)
Deferred compensation ..................................................... (404) (466)
-------------------- --------------------
Total stockholders' equity ...................................... 619,613 579,060
-------------------- --------------------
$ 1,201,787 $ 1,231,068
==================== ====================

See accompanying notes to consolidated financial statements.

HENRY SCHEIN, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)

Three Months Ended Six Months Ended
--------------------------------- ---------------------------------
June 30, 2001 June 24, 2000 June 30, 2001 June 24, 2000
--------------- --------------- --------------- ---------------
(reclassified) (reclassified)

Net sales .................................................. $ 606,285 $ 568,631 $ 1,200,180 $ 1,122,770
Cost of sales .............................................. 439,393 409,816 873,931 814,839
--------------- --------------- --------------- ---------------
Gross profit .......................................... 166,892 158,815 326,249 307,931
Operating expenses:
Selling, general and administrative ................... 131,620 127,248 263,394 252,887
Merger and integration costs .......................... -- 585 -- 585
--------------- --------------- --------------- ---------------
Operating income ................................. 35,272 30,982 62,855 54,459
Other income (expense):
Interest income ....................................... 3,177 924 4,418 2,020
Interest expense ...................................... (4,896) (4,847) (10,264) (10,699)
Other - net ........................................... 651 (495) 297 (646)
--------------- --------------- --------------- ---------------
Income before taxes on income, minority interest
and equity in earnings of affiliates ........ 34,204 26,564 57,306 45,134
Taxes on income ............................................ 12,656 9,774 21,204 16,552
Minority interest in net income of subsidiaries ............ 794 549 1,325 1,037
Equity in earnings of affiliates ........................... 156 140 265 234
--------------- --------------- --------------- ---------------
Net income ................................................. $ 20,910 $ 16,381 $ 35,042 $ 27,779
=============== =============== =============== ===============
Net income per common share:
Basic ................................................. $ 0.49 $ 0.40 $ 0.83 $ 0.68
=============== =============== =============== ===============
Diluted ............................................... $ 0.48 $ 0.39 $ 0.81 $ 0.67
=============== =============== =============== ===============
Weighted average common shares outstanding:
Basic ................................................. 42,363 41,204 42,168 40,959
=============== =============== =============== ===============
Diluted ............................................... 43,543 41,702 43,125 41,401
=============== =============== =============== ===============

See accompanying notes to consolidated financial statements.

HENRY SCHEIN, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)

Six Months Ended
---------------------------------------------
June 30, 2001 June 24, 2000
-------------------- --------------------

Cash flows from operating activities:
Net income ................................................................ $ 35,042 $ 27,779
Adjustments to reconcile net income to net cash provided
by operating activities:
Depreciation and amortization ................................... 17,056 15,950
Provision for losses and allowances on accounts receivable ...... 950 1,294
Benefit for deferred income taxes ............................... (1,581) (654)
Undistributed earnings of affiliates ............................ (265) (234)
Minority interest in net income of subsidiaries ................. 1,325 1,037
Other ........................................................... 83 --
Changes in operating assets and liabilities (net of purchase acquisitions):
(Increase) decrease in accounts receivable ........................... (375) 26,190
Decrease in inventories .............................................. 13,032 7,331
Decrease in other current assets ..................................... 13,774 815
Decrease in accounts payable and accruals ............................ (49,762) (14,163)
-------------------- --------------------
Net cash provided by operating activities ...................................... 29,279 65,345
-------------------- --------------------

Cash flows from investing activities:
Capital expenditures ...................................................... (12,986) (11,573)
Business acquisitions, net of cash acquired ............................... -- (1,171)
Other ..................................................................... (1,031) 1,135
-------------------- --------------------
Net cash used in investing activities .......................................... (14,017) (11,609)
-------------------- --------------------

Cash flows from financing activities:
Principal payments on long-term debt ...................................... (3,889) (2,762)
Proceeds from issuance of stock upon exercise of stock
options by employees .................................................. 10,381 545
Proceeds from borrowings from banks ...................................... 5,340 5,661
Payments on borrowings from banks ......................................... (10,868) (39,982)
Other ..................................................................... (175) 960
-------------------- --------------------
Net cash provided by (used in) financing activities ............................ 789 (35,578)
-------------------- --------------------
Net increase in cash and cash equivalents ...................................... 16,051 18,158
Effect of foreign exchange rate changes on cash ................................ 1,434 1,723
-------------------- --------------------
Cash and cash equivalents, beginning of period ................................. 58,362 26,019
-------------------- --------------------
Cash and cash equivalents, end of period ....................................... $ 75,847 $ 45,900
==================== ====================

See accompanying notes to consolidated financial statements.

HENRY SCHEIN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except employee and per share data)
(unaudited)

Note 1. Basis of Presentation

The consolidated financial statements include the accounts of Henry
Schein, Inc. and its wholly-owned and majority-owned subsidiaries (collectively,
the "Company").

In the opinion of the Company's management, the accompanying unaudited
consolidated financial statements contain all adjustments (consisting of only
normal recurring adjustments) necessary to present fairly the information set
forth therein. These consolidated financial statements are condensed and
therefore do not include all of the information and footnotes required by
accounting principles generally accepted in the United States for complete
financial statements. The consolidated financial statements should be read in
conjunction with the Company's consolidated financial statements and notes
thereto included in the Company's Annual Report on Form 10-K for the year ended
December 30, 2000. The Company follows the same accounting policies in
preparation of interim financial statements. The results of operations and cash
flows for the six months ended June 30, 2001 are not necessarily indicative of
the results to be expected for the fiscal year ending December 29, 2001 or any
other period. Certain amounts from prior periods have been reclassified to
conform to the current period's presentation.

Note 2. Accounting Policy - Derivative Financial Instruments

The Company uses derivatives to reduce its exposure to fluctuations in
foreign currencies and interest rates. Derivative products, such as foreign
currency forward contracts, are used to hedge the foreign currency market
exposures underlying certain intercompany debt and forecasted transactions with
customers and vendors. The Company also enters into interest rate swap and cap
agreements to modify the interest characteristics of its outstanding floating
rate long-term debt. The Company's accounting policies for these instruments are
based on its designation of such instruments as hedging transactions. The
Company does not enter such contracts for speculative purposes. The Company
records all derivative instruments on the balance sheet at fair value.

For derivative instruments that are designated and qualify as a fair
value hedge (i.e., hedging the exposure to changes in the fair value of an asset
or a liability or an identified portion thereof that is attributable to a
particular risk), the gain or loss on the derivative instrument as well as the
offsetting gain or loss on the hedged item attributable to the hedged risk are
recognized in earnings in the current period. For derivative instruments that
are designated and qualify as a cash flow hedge (i.e., hedging the exposure of
variability in expected future cash flows that is attributable to a particular
risk), the effective portion of the gain or loss on the derivative instrument is
reported as a component of Accumulated Comprehensive Loss (a component of
stockholders' equity) and reclassified into earnings in the same period or
periods during which the hedged transaction affects earnings. The remaining gain
or loss on the derivative instrument, if any (i.e. the ineffective portion and
any portion of the derivative instrument excluded from the assessment of
effectiveness) is recognized in earnings in the current period. For derivative
instruments not designated as hedging instruments, changes in their fair values
are recognized in earnings in the current period.

HENRY SCHEIN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(in thousands, except employee and per share data)
(unaudited)

Note 3. Business Acquisitions

In connection with the prior years' acquisitions, the Company incurred
certain merger and integration costs. The following table shows amounts paid
against the merger and integration accrual during the six months ended June 30,
2001:

Balance at Balance at
December 30, 2000 Payments June 30, 2001
--------------- --------------- ---------------

Severance and other direct costs ........... $ 747 $ (277) $ 470
Direct transaction and other
integration costs .................... 4,140 (920) 3,220
--------------- --------------- ---------------
$ 4,887 $ (1,197) $ 3,690
=============== =============== ===============

For the six months ended June 30, 2001, 11 employees received severance
and 3 were owed severance at June 30, 2001.

Note 4. Plan of Restructuring

On August 1, 2000, the Company announced a comprehensive restructuring
plan designed to improve customer service and increase profitability by
maximizing the efficiency of the Company's infrastructure. In addition to
closing or downsizing certain facilities, this world-wide initiative included
the elimination of approximately 300 positions, including open positions, or
about 5% of the total workforce, throughout all levels within the organization.
The restructuring plan was substantially completed at December 30, 2000.

The following table shows amounts paid against the restructuring
accrual during the six months ended June 30, 2001:

Adjustments
Balance at to Reflect Balance at
December 30, 2000 Payments Actual Cost June 30, 2001
--------------- --------------- --------------- ---------------

Severance costs .................................... $ 4,007 $ (3,249) $ 305 $ 1,063
Facility closing costs ............................. 3,684 (596) 289 3,377
Other professional and consulting costs ............ 1,157 (187) (594) 376
--------------- --------------- --------------- ---------------
$ 8,848 $ (4,032) $ -- $ 4,816
=============== =============== =============== ===============

For the six months ended June 30, 2001, 104 employees received
severance and 23 were owed severance at June 30, 2001.

HENRY SCHEIN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(in thousands, except employee and per share data)
(unaudited)

Note 5. Derivative Financial Instruments

On December 31, 2000, the Company adopted Statement of Financial
Accounting Standards No. 133 ("FAS 133") "Accounting for Derivative Instruments
and Hedging Activities", as amended, and interpreted, which requires that all
derivative instruments be recorded on the balance sheet at their fair value. The
impact of adopting FAS 133 on the Company's Statement of Operations and Balance
Sheet was not material.

The Company purchases short-term foreign currency forward contracts to
protect against currency exchange risks associated primarily with the ultimate
repayment of certain intercompany loans. All gains and losses relating to the
Company's foreign currency forward contracts were not material for the six
months ended June 30, 2001 and are included in the Statement of Operations under
Other-net.

In addition, to manage its exposure to changes in interest rates, the
Company has entered into an interest rate swap agreement and an interest rate
cap to hedge portions of its total long-term debt that are subject to variable
interest rates. These contracts are considered to be a hedge against changes in
the amount of future cash flows associated with the interest payments on
variable rate debt obligations.

All gains and losses recognized in earnings during the period relating
to the interest rate swap and cap were not material for the six months ended
June 30, 2001 and are included in the Statement of Operations under Interest
expense. Any values reported in Comprehensive Income will be reclassified to
earnings over the term of the agreements, through 2005. The Company does not
expect material amounts to be reclassified to earnings during 2001.

Note 6. Comprehensive Income

Net comprehensive income for the three and six months ended June 30,
2001 and June 24, 2000 is as follows:

Three Months Ended Six Months Ended
---------------------------------- ----------------------------------
June 30, 2001 June 24, 2000 June 30, 2001 June 24, 2000
--------------- --------------- --------------- ---------------

Net income ........................................... $ 20,910 $ 16,381 $ 35,042 $ 27,779
Unrealized gain (loss) on derivative instruments ..... 128 -- (91) --
Foreign currency translation adjustments ............. (2,395) (3,259) (7,329) (6,673)
--------------- --------------- --------------- ---------------
Net comprehensive income ............................. $ 18,643 $ 13,122 $ 27,622 $ 21,106
=============== =============== =============== ===============

HENRY SCHEIN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(in thousands, except employee and per share data)
(unaudited)

Note 7. Segment Data

The Company has two reportable segments, healthcare distribution and
technology. The healthcare distribution segment, which is comprised of the
Company's dental, medical, veterinary and international business groups,
distributes healthcare products (primarily consumable) and services to
office-based healthcare practitioners and professionals primarily in the
combined North American and European markets. Products, which are similar for
each business group, are maintained and distributed from strategically located
distribution centers in North America and Europe. The technology segment
consists primarily of the Company's practice management software business and
certain other value-added products and services which are distributed primarily
to healthcare professionals in the North American market.

The Company's reportable segments are strategic business units that offer
different products and services, albeit to the same customer base. Most of the
technology business was acquired as a unit, and the management at the time of
acquisition was retained. The following tables present information about the
Company's business segments:

Three Months Ended Six Months Ended
----------------------------------- -----------------------------------
June 30, 2001 June 24, 2000 June 30, 2001 June 24, 2000
--------------- --------------- --------------- ---------------

Net Sales:
Healthcare distribution (1):
Dental ......................................... $ 276,455 $ 264,973 $ 541,950 $ 519,279
Medical ........................................ 202,364 174,332 398,272 344,033
Veterinary ..................................... 13,397 14,275 26,163 27,635
International (2) .............................. 95,729 97,498 198,473 197,535
--------------- --------------- --------------- ---------------
Total healthcare distribution ............. 587,945 551,078 1,164,858 1,088,482
Technology (3) ...................................... 18,340 17,553 35,322 34,288
--------------- --------------- --------------- ---------------
$ 606,285 $ 568,631 $ 1,200,180 $ 1,122,770
=============== =============== =============== ===============

- ------------------------------

(1) Consists of consumable products, small equipment, laboratory products,
large dental equipment, branded and generic pharmaceuticals, surgical
products, diagnostic tests, infection control and vitamins.
(2) Consists of products sold in Dental, Medical and Veterinary groups in
European markets.
(3) Consists of practice management software and other value-added products and
services.

HENRY SCHEIN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(in thousands, except employee and per share data)
(unaudited)

Note 7. Segment Data -- (Continued)

Operating income:
Healthcare distribution ........................ $ 28,361 $ 25,048 $ 49,416 $ 42,391
Technology (includes merger and
integration costs of $0 and $585, and
$0 and $585, respectively) ................ 6,911 5,934 13,439 12,068
--------------- --------------- --------------- ---------------
Total ............................................... $ 35,272 $ 30,982 $ 62,855 $ 54,459
=============== =============== =============== ===============

June 30, 2001 June 24, 2000
--------------- ---------------

Total assets:
Healthcare distribution ........................ $ 1,169,396 $ 1,137,551
Technology ..................................... 99,359 83,689
--------------- ---------------
Total assets for reportable segments ................ 1,268,755 1,221,240
Receivables due from healthcare distribution
segment ................................... (58,821) (44,752)
Receivables due from technology segment ........ (8,147) (5,581)
--------------- ---------------
Consolidated total assets ........................... $ 1,201,787 $ 1,170,907
=============== ===============

Note 8. Earnings per Share

A reconciliation of shares used in calculating basic and diluted earnings per
share follows:

Basic ............................................... 42,363 41,204 42,168 40,959
Effect of assumed conversion of employee
stock options .................................. 1,180 498 957 442
--------------- --------------- --------------- ---------------
Diluted ............................................. 43,543 41,702 43,125 41,401
=============== =============== =============== ===============

Options to purchase approximately 1,084,000, 3,483,000, 1,535,000, and
3,896,000 shares of common stock at prices ranging from $37.50 to $46.00, $16.53
to $46.00, $34.52 to $46.00 and $15.48 to $46.00 per share that were outstanding
during the three months ended and six months ended June 30, 2001 and June 24,
2000, respectively, were excluded from the computation of diluted earnings per
share for each of the respective periods because the options' exercise prices
exceeded the fair market value of the Company's common stock.

HENRY SCHEIN, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - (continued)
(in thousands, except employee and per share data)
(unaudited)

Note 9. Effect of Recently Issued Accounting Standards

In June 2001, the Financial Accounting Standards Board finalized FASB
Statements No. 141, Business Combinations ("FAS 141"), and No. 142, Goodwill and
Other Intangible Assets ("FAS 142"). FAS 141 requires the use of the purchase
method of accounting and prohibits the use of the pooling-of-interests method of
accounting for business combinations initiated after June 30, 2001. FAS 141 also
requires that the Company recognize acquired intangible assets apart from
goodwill if the acquired intangible assets meet certain criteria. FAS 141
applies to all business combinations initiated after June 30, 2001 and for
purchase business combinations completed on or after July 1, 2001. It also
requires, upon adoption of FAS 142, that the Company reclassifies, if necessary,
the carrying amounts of intangible assets and goodwill based on the criteria in
FAS 141.

FAS 142 requires, among other things, that companies no longer amortize
goodwill, but instead test goodwill for impairment at least annually. In
addition, FAS 142 requires that the Company identify reporting units for the
purposes of assessing potential future impairments of goodwill, reassess the
useful lives of other existing recognized intangible assets, and cease
amortization of intangible assets with an indefinite useful life. An intangible
asset with an indefinite useful life should be tested for impairment in
accordance with the guidance in FAS 142. FAS 142 is required to be applied in
fiscal years beginning after December 15, 2001 to all goodwill and other
intangible assets recognized at that date, regardless of when those assets were
initially recognized. FAS 142 requires the Company to complete a transitional
goodwill impairment test six months from the date of adoption. The Company is
also required to reassess the useful lives of other intangible assets within the
first interim quarter after adoption of FAS 142.

Certain of the Company's business combinations effected prior to
June 30, 2001 were accounted for using the pooling-of-interests method. The
pooling-of-interest method does not result in the recognition of acquired
goodwill or other intangible assets. As a result, the adoption of FAS 141 and
FAS 142 will not have any effect with respect to the Company's prior
transactions that were accounted for under the pooling-of-interests method.
However, all future business combinations will be accounted for under the
purchase method, which may result in the recognition of goodwill and other
intangible assets. With respect to the Company's business comnbinations that
were effected prior to June 30, 2001, using the purchase method of accounting,
the net carrying amounts of the resulting goodwill and other intangible assets
as of June 30, 2001 were $270,328 and $8,440, respectively. Amortization expense
during the six-month period ended June 30, 2001 was $5,869. At present, the
Company is currently assessing, but has not yet determined, the impact the
adoption of FAS 141 and FAS 142 will have on its financial position and results
of operations.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

The following discussion and analysis of our consolidated financial
condition and consolidated results of operations should be read in conjunction
with our consolidated financial statements and related notes thereto in our
Annual Report on Form 10-K for the fiscal year ended December 30, 2000.

Three Months Ended June 30, 2001 compared to Three Months Ended June 24, 2000

Net sales increased $37.7 million, or 6.6%, to $606.3 million for the
three months ended June 30, 2001 from $568.6 million for the three months ended
June 24, 2000. Of the $37.7 million increase, approximately $36.9 million, or
97.9%, represented a 6.7% increase in the Company's healthcare distribution
business. As part of this increase, approximately $28.1 million represented a
16.1% increase in the Company's medical business, $11.5 million represented a
4.3% increase in its dental business, $(1.8) million represented a 1.8% decrease
in its international business, and $(0.9) million represented a 6.2% decrease in
its veterinary business. The increase in medical net sales was primarily
attributable to increased sales to core physicians office, alternate care, and
the injectables markets. In the dental market, the increase in net sales was
primarily due to increased account penetration. In the international market, the
decrease in net sales was primarily due to unfavorable exchange rates to the
U.S. dollar, partially offset by increased account penetration in Germany,
France and Spain. Had net sales for the international market been translated at
the same rates as 2000, international net sales would have increased by 5.3%. In
the veterinary market, the decrease in net sales was primarily due to a loss of
a product line. The remaining increase in second quarter 2001 net sales was due
to the technology business, which increased $0.8 million, or 4.5%, to $18.3
million for the three months ended June 30, 2001, from $17.5 million for the
three months ended June 24, 2000. The increase in technology and value-added
product net sales was primarily due to increased sales of practice management
software products and related services.

Gross profit increased by $8.1 million, or 5.1%, to $166.9 million for
the three months ended June 30, 2001 from $158.8 million for the three months
ended June 24, 2000. Gross profit margin decreased 0.4% to 27.5% from 27.9% for
the same period last year. Healthcare distribution gross profit increased $6.7
million, or 4.6%, to $153.8 million for the three months ended June 30, 2001
from $147.1 million for the three months ended June 24, 2000. Healthcare
distribution gross profit margin decreased by 0.5% to 26.2% for the three months
ended June 30, 2001 from 26.7% for the three months ended June 24, 2000,
primarily due to changes in sales mix. Technology gross profit increased by $1.4
million or 12.0% to $13.1 million for the three months ended June 30, 2001 from
$11.7 million for the three months ended June 24, 2000, primarily, due to sales
volume. Technology gross profit margins increased by 4.4% to 71.2% for three
months ended June 30, 2001 from 66.8% for the three months ended June 24, 2000,
primarily due to changes in sales mix.

Selling, general and administrative expenses increased by $4.4 million,
or 3.5%, to $131.6 million for the three months ended June 30, 2001 from $127.2
million for the three months ended June 24, 2000. Selling and shipping expenses
increased by $4.7 million, or 6.1%, to $81.7 million for the three months ended
June 30, 2001 from $77.0 million for the three months ended June 24, 2000. As a
percentage of net sales, selling and shipping expenses remained constant at
13.5% for the three months ended June 30, 2001 and for the three months ended
June 24, 2000. General and administrative expenses decreased $(0.3) million, or
0.6%, to $49.9 million for the three months ended June 30, 2001 from $50.2
million

for the three months ended June 24, 2000. As a percentage of net sales, general
and administrative expenses decreased 0.6% to 8.2% for the three months ended
June 30, 2001 from 8.8% for the three months ended June 24, 2000. The decrease
was primarily due to reductions in payroll expenses associated with the
Company's restructuring program announced in the third quarter of last year.

Other income (expense) - net decreased by $3.3 million, to $(1.1)
million for the three months ended June 30, 2001, compared to $(4.4) million
for the three months ended June 24, 2000, due primarily to higher interest
income on long-term loans receivables, and short term investments, higher
finance charge income on trade accounts receivable and foreign currency gains.

Equity in earnings of affiliates increased $0.1 million to $0.2 million
for the three months ended June 30, 2001 from $0.1 million for the three months
ended June 24, 2000.

For the three months ended June 30, 2001 the Company's effective tax
rate was 37.0%. The difference between the Company's effective tax rate and the
Federal statutory rate relates primarily to state income taxes. For the three
months ended June 24, 2000, the Company's effective tax rate was 36.8%.
Excluding merger and integration costs, none of which were deductible for income
tax purposes, the Company's effective tax rate would have been 36.0%. The
difference between the Company's effective tax rate and the Federal statutory
rate relates primarily to state income taxes.

Six Months Ended June 30, 2001 compared to Six Months Ended June 24, 2000

Net sales increased $77.4 million, or 6.9%, to $1,200.2 million for the
six months ended June 30, 2001 from $1,122.8 million for the six months ended
June 24, 2000. Of the $77.4 million increase, approximately $76.4 million, or
98.7%, represented a 7.0% increase in the Company's healthcare distribution
business. As part of this increase approximately $54.2 million represented a
15.8% increase in the Company's medical business, $22.6 million represented a
4.4% increase in its dental business, $1.0 million represented a 0.5% increase
in its international business and $(1.4) million represented a 5.1% decrease in
its veterinary business. The increase in medical net sales was primarily
attributable to increased sales to core physicians office, alternate care, and
the injectables markets. In the dental market, the increase in net sales was
primarily due to increased account penetration. In the international market, the
increase in net sales was primarily due to increased account penetration in
France, Germany, and Spain offset by unfavorable exchange rates to the U.S.
dollar. Had net sales for the international market been translated at the same
rates as 2000, international net sales would have increased by 8.2%. In the
veterinary market, the decrease in net sales was primarily due to a loss of a
product line. The remaining increase in 2001 net sales was due to the technology
business, which increased $1.0 million, or 2.9%, to $35.3 million for the six
months ended June 30, 2001, from $34.3 million for the six months ended June 24,
2000. The increase in technology and value-added product net sales was primarily
due to increased sales of practice management software products and related
services.

Gross profit increased by $18.3 million, or 5.9%, to $326.2 million for
the six months ended June 30, 2001 from $307.9 million for the six months ended
June 24, 2000. Gross profit margin decreased 0.2% to 27.2% from 27.4% for the
same period last year. Healthcare distribution gross profit increased $15.9
million, or 5.6%, to $300.8 million for the six months ended June 30, 2001 from
$284.9 million for the six months ended June 24, 2000. Healthcare distribution
gross profit margin decreased by 0.4% to 25.8% for the six months ended June 30,
2001 from 26.2% for the six months ended June 24, 2000, primarily due to changes
in sales mix. Technology gross profit increased by $2.4 million or 10.4% to

$25.4 million for the six months ended June 30, 2001 from $23.0 million for the
six months ended June 24, 2000 primarily due to sales volume. Technology gross
profit margins increased by 4.9% to 72.0% for the six months ended June 30, 2001
from 67.1% for the six months ended June 24, 2000, primarily due to changes in
sales mix.

Selling, general and administrative expenses increased by $10.5
million, or 4.2%, to $263.4 million for the six months ended June 30, 2001 from
$252.9 million for the six months ended June 24, 2000. Selling and shipping
expenses increased by $6.2 million, or 4.0%, to $159.3 million for the six
months ended June 30, 2001 from $153.1 million for the six months ended June 24,
2000. As a percentage of net sales, selling and shipping expenses decreased 0.3%
to 13.3% for the six months ended June 30, 2001 from 13.6% for the six months
ended June 24, 2000. The decrease was primarily due to reductions in payroll
expenses associated with the Company's restructuring program announced in the
third quarter of last year. General and administrative expenses increased $4.3
million, or 4.3%, to $104.1 million for the six months ended June 30, 2001 from
$99.8 million for the six months ended June 24, 2000. As a percentage of net
sales, general and administrative expenses decreased 0.2% to 8.7% for the six
months ended June 30, 2001 from 8.9% for the six months ended June 24, 2000. The
decrease was primarily due to reductions in payroll expenses also associated
with the Company's restructuring program.

Other income (expense) - net decreased by $3.8 million, to $(5.5)
million for the six months ended June 30, 2001, compared to $(9.3) million for
the six months ended June 24, 2000, due primarily to higher interest income on
long-term receivables, higher finance charge income on receivables, foreign
currency gains, and lower interest expense due to reductions in long-term debt
and bank credit line balances.

Equity in earnings of affiliates increased $0.1 million to $0.3 million
for the six months ended June 30, 2001 from $0.2 million for the six months
ended June 24, 2000.

For the six months ended June 30, 2001 the Company's effective tax rate
was 37.0%. The difference between the Company's effective tax rate and the
Federal statutory rate relates primarily to state income taxes. For the six
months ended June 24, 2000, the Company's effective tax rate was 36.7%.
Excluding merger and integration costs, none of which were deductible for income
tax purposes, the Company's effective tax rate would have been 36.2%. The
difference between the Company's effective tax rate and the Federal statutory
rate relates primarily to state income taxes.

Fluctuations in Quarterly Earnings

The Company's business has been subject to seasonal and other quarterly
fluctuations. Net sales and operating profits generally have been higher in the
fourth quarter due to purchasing patterns of office-based healthcare
practitioners and year-end promotions. Net sales and operating profits have been
lower in the first quarter, primarily due to increase purchases in the prior
quarter. Our quarterly results may also be adversely affected by a variety of
other factors, including fluctuations in exchange rates associated with
international operations, the timing of acquisitions and related costs, the
effectiveness of sales and marketing programs and adverse weather conditions.

Effect of Recently Issued Accounting Standards

Euro Conversion

Effective January 1, 1999, 11 of the 15 member countries of the
European Union have adopted the Euro as their common legal currency. On that
date, the participating countries established fixed Euro conversion rates
between their existing sovereign currencies and the Euro. The Euro now trades on
currency exchanges and is available for non-cash transactions. The participating
countries now issue sovereign debt exclusively in Euro, and have re-denominated
outstanding sovereign debt. The authority to direct monetary policy for the
participating countries, including money supply and official interest rates for
the Euro, is now exercised by the new European Central Bank.

Beginning on January 1, 2002, Euro banknotes and coins will be put into
circulation. There will be a changeover period of two months where there will be
dual circulation - where both Euro and national

currencies will be used together. Following the changeover period, the national
currencies will be completely replaced by the Euro.

The Company is currently addressing the impact of the Euro on its
information systems as well as product and customer concerns. The Company
expects to achieve timely Euro information system and product readiness, so as
to conduct transactions in the Euro, in accordance with implementation schedules
as they are established by the European Commission. The Company does not
anticipate that the costs of the overall effort will have a material adverse
impact on future results.

E-Commerce

Traditional healthcare supply and distribution relationships are being
challenged by electronic on-line commerce solutions. The Company's distribution
business is characterized by rapid technological developments and intense
competition. The rapid evolution of on-line commerce will require continuous
improvement in performance, features and reliability of Internet content and
technology by the Company, particularly in response to competitive offerings.
Through the Company's proprietary technologically based suite of products,
customers are offered a variety of competitive alternatives. The Company
believes that its tradition of reliable service, proven name recognition, and
large customer base built on solid customer relationships makes it well situated
to participate fully in this rapidly growing aspect of the distribution
business. The Company is exploring ways and means of improving and expanding its
Internet presence and will continue to do so. In January 2001, the Company
announced the unveiling of a new website (http://www.henryschein.com), which
includes an array of value-added features. As part of this effort, the Company
also launched http://www.sullivanschein.com for its office-based dental
practitioner customers.

LIQUIDITY AND CAPITAL RESOURCES

The Company's principal capital requirements have been to fund (a)
repayments on bank borrowings, (b) capital expenditures and (c) working capital
needs resulting from increased sales, and special inventory forward buy-in
opportunities. Since sales tend to be strongest during the fourth quarter and
special inventory forward buy-in opportunities are most prevalent just before
the end of the year, the Company's working capital requirements have been
generally higher from the end of the third quarter to the end of the first
quarter of the following year. The Company has financed its business primarily
through operations, its revolving credit facilities, private placement loans and
stock issuances.

Net cash provided by operating activities for the six months ended June
30, 2001 of $29.3 million resulted primarily from net income of $35.0 million,
non-cash charges of approximately $17.6 million, offset by a net increase of
cash used in operating items of working capital of approximately $23.3 million.
The increase in working capital needs was primarily due to a decrease in
accounts payable and other accrued expenses of $49.7 million, mostly due to
payments made to vendors for year-end inventory buy-ins, and a $0.4 million
increase in accounts receivable, offset by a $13.8 million decrease in other
current assets and a $13.0 million decrease in inventory. The Company
anticipates future increases in working capital requirements as a result of its
continued sales growth, extended payment terms and special inventory forward
buy-in opportunities.

Net cash used in investing activities for the six months ended June 30,
2001 of $14.0 million resulted primarily from cash used for capital expenditures
of $13.0 million. The Company expects that it will

invest more than $45.0 million during the year ending December 29, 2001, in
capital projects to modernize and expand its facilities and infrastructure
systems and integrate operations.

Net cash provided by financing activities for the six months ended June
30, 2001 of $0.8 million resulted primarily from proceeds from the issuance of
stock upon exercise of stock options of $10.4 million, offset primarily by net
debt repayments of $9.4 million.

Certain holders of minority interests in acquired entities or ventures
have the right at certain times to require the Company to acquire their interest
at either fair market value or a formula price based on earnings of the entity.

The Company's cash and cash equivalents as of June 30, 2001 of $75.8
million consist of bank balances and investments in commercial paper rated AAA
by Moody's (or an equivalent rating). These investments have staggered maturity
dates, none of which exceed three months, and have a high degree of liquidity
since the securities are actively traded in public markets.

The Company has a $150.0 million revolving credit facility, which has a
termination date of August 15, 2002, none of which had been borrowed at June 30,
2001. The Company also has one uncommitted bank line of $15.0 million, none of
which had been borrowed at June 30, 2001. Certain of the Company's subsidiaries
have revolving credit facilities that total approximately $43.2 million at June
30, 2001, under which $9.1 million has been borrowed.

On June 30, 1999 and September 25, 1998, the Company completed private
placement transactions under which it issued $130.0 million and $100.0 million,
respectively, in Senior Notes, the proceeds of which were used respectively, for
the permanent financing of its acquisitions of General Injectables and Vaccines
and the Heiland Group, as well as repaying and retiring a portion of four
uncommitted bank lines and to pay down amounts owed under its revolving credit
facility. The $130.0 million notes come due on June 30, 2009 and bear interest
at a rate of 6.94% per annum. Principal payments totaling $20.0 million are due
annually starting September 25, 2006 on the $100.0 million notes and bear
interest at a rate of 6.66% per annum. Interest on both notes are payable
semi-annually.

The Company believes that its cash and cash equivalents of $75.8
million as of June 30, 2001, its ability to access public and private debt and
equity markets, and the availability of funds under its existing credit
agreements will provide it with sufficient liquidity to meet its currently
foreseeable short-term and long-term capital needs.

Disclosure Regarding Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a "safe
harbor" for forward-looking statements. Certain information in this Form 10-Q
contains information that is forward-looking, such as the Company's
opportunities to increase sales through, among other things, acquisitions; its
exposure to fluctuations in foreign currencies; its anticipated liquidity and
capital requirements; competitive product and pricing pressures and the ability
to gain or maintain share of sales in global markets as a result of actions by
competitors; and the results of legal proceedings. The matters referred to in
forward-looking statements could be affected by the risks and uncertainties
involved in the Company's business. These risks and uncertainties include, but
are not limited to, the effect of economic and market conditions, the impact of
the consolidation of health care practitioners, the impact of health care
reform, opportunities

for acquisitions and the Company's ability to effectively integrate acquired
companies, the acceptance and quality of software products, acceptance and
ability to manage operations in foreign markets, the ability to maintain
favorable supplier arrangements and relationships, possible disruptions in the
Company's computer systems or telephone systems, possible increases in shipping
rates or interruptions in shipping service, the level and volatility of interest
rates and currency values, economic and political conditions in international
markets, including civil unrest, government changes and restrictions on the
ability to transfer capital across borders, the impact of current or pending
legislation, regulation and changes in accounting standards and taxation
requirements, environmental laws in domestic and foreign jurisdictions, as well
as certain other risks described in this Form 10-Q and prior SEC filings.
Subsequent written and oral forward looking statements attributable to the
Company or persons acting on its behalf are expressly qualified in their
entirety by the cautionary statements in this paragraph and elsewhere described
in this Form 10-Q and prior SEC filings.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There were no material changes to the disclosures made in our report
10-K for the year ended December 30, 2000, on this matter.

PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS

The Company's business involves a risk of product liability claims and
other claims in the ordinary course of business, and from time to time the
Company is named as a defendant in cases as a result of its distribution of
pharmaceutical and other healthcare products. As of June 30, 2001, the Company
was named a defendant in approximately 70 product liability cases. Of these
claims, 54 involve claims made by healthcare workers who claim allergic reaction
relating to exposure to latex gloves. In each of these cases, the Company acted
as a distributor of both brand name and "Henry Schein" private brand latex
gloves, which were manufactured by third parties. To date, discovery in these
cases has generally been limited to product identification issues. The
manufacturers in these cases have withheld indemnification of the Company
pending product identification; however, the Company is taking steps to implead
those manufacturers into each case in which the Company is a defendant. The
Company is also a named defendant in nine lawsuits involving the sale of
phentermine and fenfluramin. Plaintiffs in the cases allege injuries from the
combined use of the drugs known as "Phen/fen." The Company expects to obtain
indemnification from the manufacturers of these products, although this is
dependent upon, among other things, the financial viability of the manufacturer
and their insurers.

In Texas District Court, Travis County, the Company and one of its
subsidiaries are defendants in a matter entitled Shelly E. Stromboe & Jeanne N.
Taylor, on Behalf of Themselves and All Other Similarly Situated vs. Henry
Schein, Inc., Easy Dental Systems, Inc. and Dentisoft, Inc., Case No. 98-00886.
This complaint alleges among other things, negligence, breach of contract, fraud
and violations of certain Texas commercial statutes involving the sale of
certain practice management software products sold prior to 1998 under the Easy
Dental(R) name. In October 1999, the Court, on motion, certified both a
Windows(R) Sub-Class and a DOS Sub-Class to proceed as a class action pursuant
to Tex. R.Civ. P.42. It is estimated that 5,000 Windows(R) customers and 15,000
DOS customers could be covered by the judge's ruling. In November of 1999, the
Company filed an interlocutory appeal of the District Court's determination to
the Texas Court of Appeals on the issue of whether this case was properly
certified as a class action. On September 14, 2000, the Court of Appeals
affirmed the District Court's certification order. On January 5, 2001, the
Company filed a Petition for Review in the Texas Supreme Court asking this court
to find "conflicts jurisdiction" to permit review of the District Court's
certification order, which appeal is now pending. On April 5, 2001 the Texas
Supreme Court requested that the parties file briefs on the merits. During the
appeal of the class certification, a trial on the merits is stayed. The Company
intends to vigorously defend itself against this claim, as well as all other
claims, suits and complaints.

The Company has various insurance policies, including product liability
insurance, covering risks and in amounts it considers adequate. In many cases in
which the Company has been sued in connection with products manufactured by
others, the Company is provided by indemnification by the manufacturer There can
be no assurance that the coverage maintained by the Company is sufficient or
will be available in adequate amounts or at a reasonable cost, or that
indemnification agreements will provide adequate protection for the Company. In
the opinion of the Company, all pending matters are covered by insurance or will
not otherwise seriously harm the Company's financial condition.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

At the Company's Annual Meeting of Stockholders held on June 6, 2001,
the stockholders of the Company took the following actions:

(i) Re-elected the following individuals to the Company's Board of
Directors:

Stanley M. Bergman (37,247,343 shares voting for; 1,741,228 shares withheld)
James P. Breslawski (37,248,541 shares voting for; 1,740,030 shares withheld)
Gerald A. Benjamin (37,245,743 shares voting for; 1,742,828 shares withheld)
Leonard A. David (37,291,614 shares voting for; 1,696,957 shares withheld)
Mark E. Mlotek (37,288,102 shares voting for; 1,700,469 shares withheld)
Steven Paladino (37,294,979 shares voting for; 1,693,592 shares withheld)
Barry J. Alperin (37,836,820 shares voting for; 1,151,751 shares withheld)
Pamela Joseph (37,839,890 shares voting for; 1,148,681 shares withheld)
Donald J. Kabat (37,836,808 shares voting for; 1,151,763 shares withheld)
Marvin H. Schein (37,663,520 shares voting for; 1,325,051 shares withheld)
Irving Shafran (37,838,498 shares voting for; 1,150,073 shares withheld)

(ii) Approved the amendment to the Company's 1994 Stock Option Plan
(35,645,686 shares voting for; 3,032,297 shares voting against; 306,938
abstaining).

(iii) Approved the 2001 Section 162(m) Cash Bonus Plan (37,855,597
shares voting for; 824,106 shares voting against; 308,218 abstaining).

(iv) Ratified the selection of BDO Seidman, LLP as the Company's
independent auditors for the year ended December 29, 2001 (38,731,996
shares voting for; 210,803 shares voting against; 45,122 abstaining).

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a) Exhibits.

10.1 The Company's 1994 Stock Option Plan, as amended and
restated, as of June 6, 2001. Amendment on June 6, 2001 increased the
number of shares of Common Stock issuable upon exercise of options by
1,600,000. (Incorporated by reference to the final appendix to the
Company's revised definitive Proxy Statement on Form 14A, filed on May
2, 2001)

10.2 The Company's 2001 Section 162(m) Cash Bonus Plan
(Incorporated by reference to Appendix B to the Company's
revised definitive Proxy Statement on Form 14A, filed on May 2,
2001)

(b) Reports on Form 8-K.

None.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.

HENRY SCHEIN, INC.
(Registrant)

By: /s/ Steven Paladino
-------------------------------------------
STEVEN PALADINO
Executive Vice President and
Chief Financial Officer and Director
(principal financial officer and accounting
officer)

Dated: August 14, 2001